FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention relates to conjugates of an antibody and a drug which bind human cMET and are intended for use in treating patients with cancer.
EFFECT: disclosed are conjugates of cMET antibody and a medicinal agent and methods of using said conjugates.
4 cl, 21 dwg, 9 tbl, 20 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES TO CD40 AND THEIR APPLICATION METHODS | 2017 |
|
RU2752049C2 |
| ANTIBODIES TO PD-1(CD279) | 2017 |
|
RU2752562C2 |
| ANTI-c-MET DRUG CONJUGATE AND USE THEREOF | 2021 |
|
RU2822497C1 |
| ANTI-OX40 ANTIBODIES AND THEIR APPLICATION | 2017 |
|
RU2753493C2 |
| ANTI-HER2 BIPARATOPIC ANTIBODY-DRUG CONJUGATES AND METHODS OF THEIR APPLICATION | 2019 |
|
RU2806049C2 |
| ANTIBODIES AGAINST CD79b, DRUG CONJUGATES AND THEIR USE | 2019 |
|
RU2805251C2 |
| ANTIBODIES AND ANTIBODY FRAGMENTS FOR SITE-SPECIFIC CONJUGATION | 2016 |
|
RU2757815C2 |
| SITE-SPECIFIC HER2 ANTIBODY-DRUG CONJUGATES | 2016 |
|
RU2745565C2 |
| DRUG CONJUGATES FROM MONOCLONAL CMET BINDING AGENTS AND THEIR USE | 2019 |
|
RU2813828C2 |
| SEZ6 ANTIBODY-DRUG CONJUGATE AND METHODS FOR APPLICATION | 2019 |
|
RU2770474C1 |
